Science

SCIENCE OF REG1

The REG1 Anticoagulant System is a two-component system consisting of an aptamer-based anticoagulant and its complementary active control agent.

The REG1 anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to blood coagulation Factor IXa, inhibiting its activity and preventing blood clot formation. The active control agent, RB007, consists of a nucleotide sequence complementary to RB006. Binding of RB007 to RB006 releases RB006 from Factor IXa, causing the predictable and rapid reversal of its anticoagulant effect and allowing the patient’s blood to return to normal. Because binding of RB007 to RB006 is energetically favored and irreversible, reversal of the anticoagulant activity of RB006 by RB007 is sustained.

By adjusting the dose of RB007, physicians can reverse partially or completely the activity of RB006, titrating the anticoagulant effect based on each patient’s individual needs in each clinical setting. For this reason, Regado believes REG1 has the potential to be the anticoagulant therapy of choice from the emergency room to the operating room.

REG1 Mechanism of Action:

Coagulation proceeds unimpeded and clotting proceeds		RB006 selectivelyinhibits Factor IXa andclotting cannot proceed		RB007 binds to RB006; the resulting complex is incapable of inhibiting Factor IXa and clotting cascade resumes